Flt3L treatment of bone marrow donors increases graft plasmacytoid dendritic cell content and improves allogeneic transplant outcomes

Higher numbers of donor plasmacytoid dendritic cells (pDC) increased survival and reduced graft-versus-host disease (GvHD) in human recipients of unrelated donor bone marrow (BM), but not G-CSF peripheral blood grafts. In murine models, we have shown that donor BM pDC increase survival and decrease GvHD compared to G-CSF-mobilized pDC. To increase the content of pDC in BM grafts we studied the effect of FMS-like tyrosine kinase 3 ligand (Flt3L) treatment of murine BM donors on transplant outcomes.

Source: Biology of Blood and Marrow Transplantation - November 29, 2018 Category: Hematology Authors: Mojibade Hassan, Alina Ulezko Antonova, Jian Ming Li, Sakura Hosoba, Manali Rupji, Jeanne Kowalski, Adam J. Perricone, David L. Jaye, Henry Marsh, Michael Yellin, Steven Devine, Edmund K. Waller Source Type: research